This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
pot-stocks: Archive
TLRY Stock Loses 17% in Three Months: Should You Buy, Hold or Sell?
by Sundeep Ganoria
Tilray's revenues and EBITDA are growing, but weak margins, negative cash flow and competition raise questions about its next move.
TLRYNegative Net Change CGCNegative Net Change ACBPositive Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Cannabis Stock CRLBF Surges 10% in a Month: Time to Buy or Sell?
by Sundeep Ganoria
Cresco's 10% monthly rally reflects stronger revenues, organic growth and margins, but competition and normalization risks cloud the outlook.
CRLBFNegative Net Change ACBPositive Net Change CURLFNegative Net Change VRNONegative Net Change
marijuana medical pot-stocks
Cannabis Stock VRNO Rises 10% in a Month: Time to Buy, Hold or Sell?
by Sundeep Ganoria
Verano's rally follows strong Q2 results, but margin pressure and wider 2026 losses keep the stock in wait-and-watch mode.
VRNONegative Net Change ACBPositive Net Change GTBIFNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?
by Sundeep Ganoria
Canopy Growth's cannabis business is showing signs of a turnaround, with revenue growth, improving margins and a narrower EBITDA loss fueling its rally.
CGCNegative Net Change TLRYNegative Net Change ACBPositive Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Should You Buy ACB Stock Amid Curaleaf's Hostile Takeover Attempt?
by Sundeep Ganoria
Aurora Cannabis faces a potential Curaleaf takeover at a 45% premium, but investors must weigh the offer against ACB's standalone prospects.
ACBPositive Net Change TLRYNegative Net Change CURLFNegative Net Change
marijuana medical pot-stocks
Should You Buy, Hold or Sell GTBIF Stock Post Q2 Earnings Release?
by Sundeep Ganoria
Green Thumb tops Q2 earnings and sales estimates, but can regulatory catalysts, buybacks and expansion plans outweigh pricing pressure and fierce competition?
GTBIFNegative Net Change TLRYNegative Net Change TRLVNegative Net Change
marijuana medical pot-stocks
VFF Stock Loses 27% in Three Months: Time to Invest or Exit?
by Sundeep Ganoria
Village Farms has slid 27% in three months despite strong international cannabis growth. Can European expansion outweigh rising competition and pricing risks?
VFFNegative Net Change TLRYNegative Net Change ACBPositive Net Change
marijuana medical pot-stocks
TLRY Plans Strategic Medical Cannabis Expansion: Time to Buy or Sell?
by Sundeep Ganoria
Tilray expands its medical cannabis strategy with HelloMD, adding virtual patient access as investors weigh growth potential against ongoing profitability challenges.
TLRYNegative Net Change CRONPositive Net Change ACBPositive Net Change
marijuana medical pot-stocks
CRON Strengthens Global Footprint: Is the Cannabis Stock Worth Buying?
by Sundeep Ganoria
Cronos Group posts 40% Q1 revenue growth, gains share in Canada and expands abroad, but fierce cannabis competition keeps investors cautious.
CRONPositive Net Change TLRYNegative Net Change ACBPositive Net Change
marijuana medical pot-stocks
GTBIF Stock Climbs 17.5% in Three Months: Time to Invest or Cash Out?
by Sundeep Ganoria
Green Thumb has surged 17.5% in three months as regulatory progress, Q1 growth and buybacks lift sentiment, but competition and pricing pressure persist.
GTBIFNegative Net Change CRLBFNegative Net Change TRLVNegative Net Change
marijuana medical pot-stocks